By Fineline Cube 
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced that its investee company Jiangsu Haoxinqing Mobile Healthcare Technology Co., Ltd. is planning to pursue an overseas listing, though the specific location remains undisclosed. To facilitate this, the founding shareholders have established Good Mood Holding Limited in the Cayman Islands as the holding entity and future listing vehicle.
Jiangsu Haoxinqing’s Business Scope
Jiangsu Haoxinqing positions itself as a specialized, sophisticated, and innovative enterprise in the psychological healthcare sector. It is recognized as China’s first digital high-tech group corporation offering full-cycle solutions in mental health. These solutions encompass science popularization and prevention, health management, disease screening, diagnosis and treatment, rehabilitation management, as well as R&D for intelligent systems and digital pharmaceutical products.
Restructuring for Overseas Listing
As part of the overseas listing process, Nhwa Pharma will execute domestic transaction agreements to exit its investment in Jiangsu Haoxinqing and enter into overseas transaction agreements with Good Mood Holding Limited. This will involve subscribing for corresponding shares to ensure that Nhwa Pharma’s equity stake remains unchanged at 19.0960% both before and after the restructuring.-Fineline Info & Tech